Medpace Surpasses Q4 EPS by 11.8% with $708.45M Revenue
Medpace delivered Q4 adjusted EPS of $4.67, surpassing the $4.18 consensus by 11.8%. Revenue reached $708.45 million, topping estimates by 4.0% and rising 32% from $536.59 million a year ago.
1. Q4 Earnings Performance
Medpace reported adjusted EPS of $4.67 for the quarter, beating the $4.18 consensus by 11.8% and up from $3.67 a year earlier. This marks the fourth straight quarter the company has outpaced earnings forecasts.
2. Revenue Results
Q4 revenue totaled $708.45 million, exceeding consensus by 4.0% and representing a 32% increase from $536.59 million in the prior-year period. The company has now topped revenue estimates in each of the last four quarters.
3. Outlook and Market Reaction
Shares have declined about 3.5% year-to-date versus a 1.3% gain for the S&P 500, reflecting investor caution despite strong results. Consensus for the upcoming quarter calls for EPS of $3.77 on $683.59 million revenue and fiscal-year EPS of $16.63 on $2.8 billion revenue.